Slide 1: Covering letter to stock exchanges: Investors Presentation
4th February, 2021 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol : KOPRAN Dear
Slide 2: Growth-Driven. Future-Focused. Kopran Limited Quarterly Presentation
An Integrated Global Pharmaceutical Company Growth-Driven. Future-Focused. Kopran Limited Quarterly Presentation February 2021 NSE ticker: KOPRAN BSE ticker: 524280 Bloomberg ticker: KOP:IN A Parijat Enterprise Company
Slide 3: Safe Harbour Statement
Safe Harbour Statement 2 This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered
Slide 4: Kopran Limited A Global Pharmaceutical Company
Kopran Limited A Global Pharmaceutical Company 3 Who we are? An integrated pharmaceutical Company, committed to supply International Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally State-of-the-art manufacturing facilities and products with various accreditations and appro
Slide 5: APIs Business Overview
APIs Business Overview 4 Kopran Research Laboratories Ltd. Dedicated and Product Segments, versatile facilities for: Anti-hypertensive Atenolol Macrolides Pregabalin Neuromodulator Cephalosporins - Non- Urological Sterile & Sterile Anti-infective/Anti-acne Macrolides Sterile Carbapenems Granules Fac
Slide 6: APIs Focus Areas
APIs Focus Areas 5 Process and yield improvement: Initiatives undertaken continuously for improving the existing product line US and other Regulated markets Emphasis on exports: Leveraging expertise and capabilities by 2 Filed in Q3 exploring, developing and commercialising US 7 Total Filings Atenol
Slide 7: APIs Products Developed/Under Development
APIs Products Developed/Under Development 6 Products under Therapeutic Pipeline Category R&D Scaleup Validation Commercialization Biapenem Carbapenem Completed Completed Completed Q4 FY 21-22 Tebipenem Carbapenem Completed Completed Completed Faropenem# Carbapenem Completed Completed Completed Q1 FY
Slide 8: APIs Segment-wise Revenue Mix
Operational Highlights APIs Segment-wise Revenue Mix 7 Q2 FY 2020-21 (` Lakhs) Q3 FY 2020-21 (` Lakhs) Steriles Urological Urological Cepholosphorin Anti-infective/Anti-acne Advance Intermediate Anti-hypertensive 43.02 Steriles 103.34 Anti-hypertensive Cepholosphorin 718.79 6.32 1,081.82 Steriles 70
Slide 9: APIs Market-wise Revenue Mix
Operational Highlights APIs Market-wise Revenue mix 8 Q2 FY 2020-21 (` Lakhs) Q3 FY 2020-21 (` Lakhs) Local Sales Local Sales 1,640.09 2,532.95 Export Sales 4,603.39 4,952.91 Export Sales Total ₹ 7,136.34 Lakhs Total ₹ 6,882.17 Lakhs
Slide 10: Way Forward
Way Forward 9 Develop niche and blockbuster products: Improve facility and enhance capacity: Developing complete range of Carbapenams to solidify Undertaking upgradation and expansion of 3 blocks at the Company’s position in the segment Mahad facility in Q4 to cater the increasing demand of Developi
Slide 11: Formulations Business Overview
Formulations Business Overview 10 Accreditations: Kopran Limited Approved by 12 countries including MHRA (UK), SAPHRA South Africa (formerly MCC), TMDA Tanzania (formerly TFDA), NDA Dedicated Facilities: Uganda, PPB Kenya, MCAZ Zimbabwe, MOH Oman, MOH Iraq, FMHACA Ethiopia, Penicillin-based MOH Yeme
Slide 12: Formulations Focus Areas and Output
Formulations Focus Areas and Output 11 Process/Technology and Yield Improvement: Development of Products and Dossiers for Continuous measures taken towards Non-Regulated Market: process/technology and yield improvement for making Develop products/formulations and file Dossiers in products more compe
Slide 13: Formulations Region-wise Sales Break-up
Operational Highlights Formulations Region-wise Sales Break-up 12 Q2 FY 2020-21 (` Lakhs) Q3 FY 2020-21 (` Lakhs) UK UK 366.01 344.18 Southeast Southeast 456.44 Asia 433.22 Asia 1,377.03 Africa South Africa 931.61 66.66 2,732.58 Africa Latem 0 Local 46.79 19.71 Local South Africa 2,291.96 Latem Tota
Slide 14: Formulations Product-wise Sales Break-up
Operational Highlights Formulations Product-wise Sales Break-up 13 Q2 FY 2020-21 (` Lakhs) Q3 FY 2020-21 (` Lakhs) Pen Plant * 1,047.35 Pen Plant 2,056.40 2,355.87 Non Pen 3,358.47 Non Pen Total ₹ 4,412.27 Lakhs Total ₹ 4,405.82 Lakhs *Penecillin products’ demand was lower due to COVID-19. However,
Slide 15: Way Forward
Way Forward 14 Developments of products and dossiers Automisation of manufacturing and To actively packaging line to participate in increase output of Regulated markets Non-Regulated markets various tenders in finished products, 4 dossiers filed in Q3 56 dossiers filed in Q3 the African region effic
Slide 16: Financial Performance
15 Financial Performance
Slide 17: Financial Highlights Quarterly Snapshot
Financial Highlights Quarterly Snapshot 16 Sales/Other Income (` Lakhs) EBIDTA * (` Lakhs) Finance Costs (` Lakhs) 2,674.50 262.30 12,440.21 12,454.44 2,536.99 11,630.41 2,363.45 222.83 10,158.25 8,755.77 186.10 174.20 1,356.16 141.69 1,108.23 Q-3 Q-4 Q-1 Q-2 Q-3 Q-3 Q-4 Q-1 Q-2 Q-3 Q-3 Q-4 Q-1 Q-2
Slide 18: Financial Ratios Building Shareholder Value Year on Year
Financial Ratios Building Shareholder Value Year on Year… 17 EBDITA & EBDITA Margin (` Lakhs, %) RoE (%) Total Debt/Equity (X) 7,574.93 RoCE (%) 0.57 33% 0.51 32.50% 21% 0.41 4,914 5,037.95 29.60% 4,696 30% 4,005 20% 17% 15% 0.29 0.29 14% 15% 13% 13% 15% 15% 11% 2017-18 2018-19 2019-20 H1 9M Q-2 Q-3
Slide 19: Consolidated Financial Highlights
Consolidated Financial Highlights 18 (` Lakhs) Particulars 9M FY 2020-21 H1 2020-21 2019-20 2018-19 Equity Share Capital 4324.89 4,324.89 4,324.89 4,324.89 Other Equity 18,651.29 17,722.32 14,643.12 12,522.68 Networth 22,976.18 22,047.21 18,968.01 16,847.57 Fixed Assets (net) 14012.88 14,012.88 14,1
Slide 20: Governance Board of Directors
Governance Board of Directors 19 Mr. Surendra Somani Mr. Adarsh Rajendra Somani Mrs. Mamta Biyani Mr. Narayan Atal Executive Vice Chairman Director Independent Director Independent Director Dr. Siddhan Subramanian Dr. Sunita Banerji Mr. Susheel Somani Mr. Varun Surendra Somani Independent Director I
Slide 21: Ownership Structure
Ownership Structure 20 Kopran Shareholding Pattern (%) Limited 2.41 Kopran Kopran Research Kopran (H.K.) Lifesciences Laboratories Limited 43.78 Limited Limited* 53.82 Kopran (UK) Limited Promoters Non-Institutions Financial Institutions
Slide 22: Contact Us
Contact Us 21 About Kopran Limited: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Develop
Slide 23: Thank You
Thank You